Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention

CNS Drugs
F Markus LewekeCathrin Rohleder

Abstract

The term schizophrenia describes a group of multifaceted psychiatric conditions causing significant impairment of the quality of life of affected patients. Although multiple pharmacological treatment options exist, e.g. first- or second-generation antipsychotics, these therapeutics often cause disturbing side effects, such as extrapyramidal symptoms, prolactin increase, sexual dysfunction and/or metabolic syndrome. Furthermore, cognitive impairments and negative symptoms, two factors significantly influencing the course and outcome, are not sufficiently addressed by the available antipsychotics. Since its discovery, multiple clinical and preclinical studies have linked the endocannabinoid system to schizophrenia. Both the endocannabinoid anandamide and the cannabinoid CB1 receptor are deeply linked to underlying disease processes. Based hereon, clinical trials in schizophrenia have explored cannabidiol, a primary component of Cannabis sativa, and rimonabant, a partial antagonist to the CB1 receptor. While the latter did not reveal positive results, cannabidiol significantly ameliorated psychotic symptoms, which was associated with an increase in anandamide serum levels. However, the exact mechanisms of the antipsychotic effects...Continue Reading

References

Jan 1, 1991·Psychopharmacology·A W ZuardiJ M Cunha
Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Jan 1, 1990·Psychopharmacology·F S GuimarãesA W Zuardi
Aug 1, 1996·Biological & Pharmaceutical Bulletin·K WatanabeH Yoshimura
Apr 16, 1999·Nature Neuroscience·A GiuffridaD Piomelli
Sep 29, 1999·Neuroreport·F M LewekeD Piomelli
Jun 6, 2000·Pharmacology, Biochemistry, and Behavior·F M LewekeH M Emrich
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C H Ashton
Feb 2, 2002·The American Journal of Psychiatry·Stefan LeuchtWerner Kissling
Aug 16, 2002·American Journal of Epidemiology·J van OsH Verdoux
Nov 26, 2002·BMJ : British Medical Journal·Louise ArseneaultTerrie E Moffitt
Nov 27, 2002·European Journal of Pharmacology·Roger G PertweeAdèle Thomas
Jan 23, 2003·Psychological Medicine·D M FergussonN R Swain-Campbell
Jun 6, 2003·Neuroscience and Biobehavioral Reviews·Albert Hung Choy Wong, Hubert H M Van Tol
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Katerina ZavitsanouXu Feng Huang
Jun 1, 2004·The American Journal of Psychiatry·Herbert Y MeltzerUNKNOWN Meta-Trial Study Group
Jun 3, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Deepak Cyril D'SouzaJohn Harrison Krystal
Sep 9, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea GiuffridaDaniele Piomelli
Mar 23, 2005·Biological Psychiatry·Deepak Cyril D'SouzaJohn Harrison Krystal
Jun 25, 2005·Schizophrenia Bulletin·Cécile HenquetJim van Os
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid A Taylor
Nov 1, 2005·Neurochemical Research·Ethan B RussoKeith K Parker
Jan 3, 2006·Neuropharmacology·Alison J DrysdaleBettina Platt
Jan 13, 2006·Journal of Psychopharmacology·Antonio Waldo ZuardiJosé Alexandre S Crippa
May 20, 2006·Experimental Brain Research·Kelly A NewellXu-Feng Huang
May 27, 2006·The Journal of Pharmacology and Experimental Therapeutics·Alessia LigrestiVincenzo Di Marzo

❮ Previous
Next ❯

Citations

Jun 30, 2019·Fundamental & Clinical Pharmacology·Fabien DespasJean-Louis Montastruc
May 23, 2019·European Archives of Psychiatry and Clinical Neuroscience·Isabel MaurusPeter Falkai
Nov 20, 2019·Therapeutic Advances in Psychopharmacology·Cathy Davies, Sagnik Bhattacharyya
Oct 10, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Catharine A MielnikRuth A Ross
Oct 30, 2020·Nutrients·Rosaria ScandiffioPatrizia Bovolin
Jun 14, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Gerwyn MorrisAndre F Carvalho
Oct 31, 2021·The European Journal of Neuroscience·Helena P G JoaquimWagner F Gattaz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Biological Psychiatry
F Markus LewekeCathrin Rohleder
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
Patrik RoserWolfram Kawohl
Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Antonio LeoMaurizio Elia
© 2022 Meta ULC. All rights reserved